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in Polyconsumer Men Under 
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Onset of Substance Use
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Neurocognition is a key factor in the development and maintenance of Substance Use Disorders 
(SUD). However, there are still several aspects that need to be studied in this area. In this study, 
we elucidate the influence of age of onset of substance use (OSU) on the clinical course and 
neuropsychological performance of substance use disorder (SUD) patients, as well as to explore the 
influence of years of education, duration of drug use and premorbid intelligence quotient (IQ) on the 
cognitive results obtained. An exhaustive neuropsychological battery was used to assess different 
cognitive domains in 80 male polyconsumers, 41 with earlier OSU (16 years or before: OSU ≤ 16) and 
39 with later OSU (17 years or later: OSU ≥ 17). The patients were under treatment with at least 4 
months of abstinence confirmed by urinalysis. The OSU ≤ 16 group presented a worse clinical state, 
as well as a lower premorbid IQ and worse performance in processing speed, visual perception and 
planning skills. The duration of drug use may account for the differences in planning and processing 
speed. In this work we discuss the premorbid or acquired nature of the cognitive deficits found.
The United Nations Office on Drugs and Crime considers substance use as a public health issue that 
has severe consequences on individuals and communities1. Despite the improvements in prevention and 
treatment of Substance Use Disorders (SUD), the world levels of consumption are significantly high2. 
This may be partly due to the fact that several genetic and environmental factors intervene in the onset 
and maintenance of SUD3, which in turn causes a wide array of clinical symptomatology4 and response 
to intervention5. Thus, it is necessary to study new ways to improve our knowledge of the ethiopatho-
genesis of SUD, its typologies and the relevant associated variables both its prevention and rehabilitation.
In this line, neuropsychology has made valuable contributions in recent years. Some studies, scarce 
but promising, indicate that incorporating cognitive rehabilitation in the treatment of addiction opti-
mizes the results of traditional interventions6,7. This is consistent with current models of development 
and maintenance of SUD where the role of biological and neurocognitive factors stands, in addition to 
environmental factors3.
Thus, it has been shown that SUD patients show alterations in cognitive functions such as inhibi-
tory or executive control8,9, working memory10 or visuospatial skills11, even before consumption onset. 
In addition, several studies support that cognitive impairment due to consumption is related to both 
duration and severity of addiction, there being dose-dependent relationships12, although more studies 
are needed to establish a reliable relationship between cognitive impairment and the severity of SUD. 
Likewise, it has been shown that the greater the cognitive impairment, poorer are the treatment out-
comes13,14. Specifically, deficits in inhibitory control and cognitive flexibility may affect the ability of 
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patients to focus attention and direct their behavior to new and alternative goals which are incompatible 
with substance use-related behaviors15.
In the study of the relationship between cognitive functions, and the development and characteristics 
of SUD, special attention has been paid to modulating factors such as the type of substance used16, the 
pattern of consumption or duration of drug use17. While some studies have also highlighted the relevance 
of the age of onset of substance use (OSU), new studies are needed to provide more robust data about 
their relationship, particularly in cases of polyconsumption or considering specific ages of OSU. However, 
in samples of alcoholic patients, an earlier OSU has been linked to increased intensity of personality 
traits linked to consumption, such as high Novelty Seeking or low Harm Avoidance6,18, worse clinical 
course4 and greater structural and functional brain alterations19. In polyconsumers, early OSU has also 
been associated with greater cognitive impairment20. Furthermore, consumption in adolescence implies 
greater cognitive impairment compared to adulthood21,22, due to the different critical periods for brain 
maturation23. Thus, the study of typologies of addicts based on their cognitive performance and their 
clinical implications considering the age of OSU is a research area of undoubted clinical interest.
In several studies with cannabis consumers, neuropsychological differences have been observed 
depending on whether consumption begins at age 16 or earlier, or at age 17 or later. Individuals with an 
earlier OSU perform lower in tasks of visual exploration24, processing speed and cognitive flexibility25; 
have lower verbal intelligence quotient (VIQ)26 and show less cerebral and gray matter volume27. The 
cut-off age used in these studies was based on three characteristics of brain ontogeny: (a) between 12 
and 15 years the network involved in visual scanning reaches its peak development28; (b) compared with 
the serotonergic system, the dopaminergic and endocannabinoid systems, which are key in prefrontal 
functioning, mature earlier29, being almost defined by the end of puberty30; (c) by age 15 there is one 
last peak in cortical changes31. However, the only study that used this cutoff age with mostly cocaine and 
alcohol consumers did not replicate earlier findings32.
Our work has three aims. The first is to study the differences in the clinical course of polyconsum-
ing men diagnosed with SUD, depending on whether they initiated substance use at age 16 or earlier 
(OSU ≤ 16) or at age 17 or later (OSU ≥ 17). The second is to assess the differences in their neuropsycho-
logical performance. Unlike previous works where only one type of cognitive function has been studied, 
in the current work we have administered a comprehensive battery of neuropsychological tests sensitive 
to the characteristics of SUD patients. Our third goal is to explore, regardless of the groups, if the age of 
patients, age of OSU, years of education, duration of drug use and the premorbid intelligence quotient 
(IQ) modulate their neurocognitive performance.
Results
Differences in sociodemographic and clinical data. With respect to sociodemographic variables, 
the OSU ≤ 16 and OSU ≥ 17 groups provided no significant differences in any of them: age, years of 
education, marital and economic status. The overall sample was aged 20 to 55 (36.45 ± 8.20) and most of 
the patients had completed the Spanish compulsory education (from 6 to 16 years, grades 1 to 10). The 
analyses of the clinical variables did indicate significant differences between groups, being more frequent 
in the OSU ≤ 16 group to have relatives with SUD (p = 0.044). See Table 1.
Regarding SUD data, the OSU ≤ 16 group had a higher rate of patients in residential rather than 
in ambulatory treatment (p = 0.003) and with a higher rate of polyconsumption (p = 0.008). They also 
had lower age of OSU (p = 0.0001), greater duration of drug use (p = 0.001) and higher rates of relapse 
(p = 0.039). The groups did not differ in the type of substance used or in the months of abstinence (see 
Table 2). In the total sample, the substances most frequently used were cocaine (95%), alcohol (77.5%) 
and cannabis (48.8%).
In the total sample, an additional analysis was carried out considering the treatment regimen (residen-
tial or ambulatory), to assess whether this was an indicator of clinical severity related to the recruitment 
of patients in both regimes and not related to the age of OSU. No significant differences between groups 
were found regarding age (t(39) = 1.899; p = 0.065), years of education (U = 549.50; p = 0.102) or scores 
in the Block Design subtest (t(39) = 1.19; p = 0.544). Instead, significant differences were found in dura-
tion of drug use (t(39) = 0.826; p = 0.030) and in the Vocabulary subtest scores (t(39) = − 0.764; p = 0.016).
Differences in neuropsychological functioning. Considering age and years of education as covar-
iates, significant differences between groups were found in the Vocabulary (p = 0.007) and Block Design 
(p = 0.019) subtests, where the OSU ≤ 16 group had a worse performance in both. This group also took 
longer (p = 0.003) to complete the Trail Making Test part A (TMT-A). Regarding the Judgment of Line 
Orientation Test (JLOT), the OSU ≤ 16 group performed worse in all the parameters measured: number 
of correct answers (p = 0.024) and reaction time (p = 0.038) (see Table 3).
In addition, in the Tower of Hanoi test the OSU ≤ 16 group required more number of movements 
(p = 0.045), committed more errors (p = 0.262) and showed a higher reaction time (p = 0.009) (see 
Table  4). No differences between groups were found in the other neuropsychological tasks: Digits 
Forward, Digits Backwards, Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test part-B 
(TMT-B), Wisconsin Card Sorting Test (WCST) and Iowa Gambling Test (IGT).
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Influence on neuropsychological functioning of age of onset of substance use, age, years 
of education, duration of drug use, premorbid verbal and performance IQ. First, comparing 
cognitive performance taking age, years of education, duration of drug use and score in Vocabulary 
and Block Design as covariates eliminated intergroup differences observed previously (see Table 3 and 
Table 4).
Second, considering the total sample, the regression analysis indicated that the model was significant 
in only three neuropsychological tasks: TMT-A, JLOT and Tower of Hanoi (see Table 5). In these three 
cognitive domains, the significant variables were Block Design, duration of drug use and age of OSU, 
explaining more than 17% of the variance. Block Design explained 34% of the variance of the number 
of correct answers in the JLOT (p = 0.0001) and, together with age of OSU, 17% of the variance of reac-
tion time (p = 0.0001). Block Design and duration of drug use accounted for 29% of the variance in the 
TMT-A. Finally, duration of drug use explained 20% of the variance in reaction time in the Tower of 
Hanoi (p = 0.0001).
OSU ≤ 16 
(N = 41)
OSU ≥ 17 
(N = 39)
Statistical 
contrasts p values
Sociodemographic data
Age (yr) 34.83 ± 1.29 38.15 ± 1.26 t = − 1.84 0.070
Years of education 10.02 ± 0.29 10.72 ± 0.43 U = 634.50 0.097
Marital status X2 = 2.49 0.646
 Single 56.1% 51.3%
 Stable partner 9.8% 5.1%
 Married 19.5% 17.9%
 Separate/Divorced 14.6% 25.6%
Economic status X2 = 4.47 0.346
 Active 22.0% 43.6%
 Disability pension 24.4% 15.4%
 Sick leave 4.9% 2.6%
 Unemployed 26.8% 20.5%
 No income 22% 17.9%
Clinical data
Relatives with SUD  U = 666.00 0.044
 Yes 24.4% 7.7%
 No 75.6% 92,3%
Relatives with psychiatric 
disorder U = 772.50 0.762
 Yes 65.9% 69.2%
 No 34,1% 30.8%
Number of suicidal attempts 0.39 ± 0.14 0.13 ± 0.05 U = 716.50 0.227
Past treatment for SUD U = 773.50 0.762
 Yes 36.4% 33.3%
 No 63.4% 66.7%
Daily number of cigarettes for 
tobacco smokers 13.05 ± 1.12 12.38 ± 1.5 U = 760.00 0.698
Fagerström Score for tobacco 
smokers U = 483.00 0.913
 Low Dependence 34.3% 32.1%
 Moderate Dependence 54.3% 57.1%
 High Dependence 11% 10.7%
Daily beverages with caffeine 2.23 ± 0.28 3.78 ± 1.24 U = 679.50 0.238
Table 1.  Descriptive statistics (frequencies or mean and standard error) of the sociodemographic and 
clinical data for the two groups and the statistical contrasts carried out. OSU ≤ 16: Onset of substance 
use at age 16 or earlier; OSU ≥ 17: Onset of substance use at age 17 or later; yr: years; SUD: Substance Use 
Disorder.
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Discussion
This study examines, for the first time, the possible existence of clinical and neurocognitive differences 
in polydrug addicts depending on whether their substance use began at age 16 or earlier, or at age 17 or 
later. In addition, we also assess the effect of age of onset, age, years of education, duration of drug use 
and premorbid IQ on cognitive performance for the total sample.
The groups did not differ in any sociodemographic parameter studied or in the main substance of 
consumption. Moreover, they did not differ in the variables that affect cognition, such as duration of 
abstinence33,34, rates of caffeine and nicotine intake35 or use of psychotropic drugs36, and therefore we 
discarded their effects on the results of neuropsychological performance.
The OSU ≤ 16 group presented a more severe clinical pattern, characterized by the presence of more 
family history of SUD, higher relapse rate, the need for a more intensive treatment regimen to achieve 
abstinence, greater duration of drug use and consumption of more substances. Only Pope et al.26 stud-
ied the family history of substance abuse in cannabis consumers, obtaining no differences between the 
OSU ≤ 16 and OSU ≥ 17 groups. However, our results on the age of OSU are revealing and link with 
the observation that, for alcoholic patients, younger ages of first use have been associated with worse 
clinical course of SUD4.
We observed several differences in neuropsychological functioning between groups. Controlling the 
effect of age and years of education, the OSU ≤ 16 group presented lower premorbid IQ in both the 
verbal component (VIQ), measured using the Vocabulary subtest and in the performance component 
(PIQ), measured through the Block Design subtest. These cognitive differences have not been found in 
cannabis addicts with brief periods of abstinence24. In contrast, consumers with age of OSU ≤ 16 and 
longer periods of abstinence, more similar to our sample, show lower VIQ26. This suggests that when 
Substance use data
OSU ≤ 16 
(N = 41)
OSU ≥ 17 
(N = 39)
Statistical 
contrasts p values
Consumption pattern
 One substance 12.2% 23.1% U = 712.50 0.203
 Two substances 22.1% 41.0% U = 647.00 0.068
 Polydrug use 65.7% 35.9% U = 560.00 0.008
Substances useda
 Cocaine 95.1% 94.9% U = 797.50 0.959
 Alcohol 82.9% 71.8% U = 710.50 0.236
 Cannabis 58.5% 38.5% U = 639.00 0.074
 Opioids 22% 15.4% U = 747.00 0.455
 Ecstasy 22% 7.7% U = 685.50 0.076
 Hallucinogens 17.1% 5.1% U = 704.00 0.093
 Sedatives 4.9% 5.1% U = 797.50 0.959
Age of OSU (yr) 14.93 ± 0.19 23.03 ± 1.12 U = 1.50 0.0001
Duration of drug use (yr) 19.39 ± 1.26 13.12 ± 1.62 t = 3.58 0.001
Typology of treatment regimen X2 = 9.12 0.003
 Residential 82.9% 51.3%
 Ambulatory 17.1% 48.7%
Number of psychotropics 
including treatment U = 689.50 0.215
 None 56.1% 71.8%
 One 26.8% 12.8%
 More than one 17.1% 15.4%
Months of abstinence 7.76 ± 0.71 8.31 ± 0.73 U = 713.00 0.399
Number of relapses 1.49 ± 0.32 0.64 ± 0.16 U = 679.50 0.039
Clinical Global Impression 
(CGI) 2.36 ± 0.23 2.16 ± 0.20 U = 681.00 0.659
Table 2.  Descriptive statistics (frequencies or mean and standard error) of data related to SUD for the 
two groups and the statistical contrasts carried out. aPercentages will not equal 100 as each participant 
may take more than one substance of abuse. OSU ≤ 16: Onset of substance use at age 16 or earlier; 
OSU ≥ 17: Onset of substance use at age 17 or later; OSU: Onset of substance use; yr: years.
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patients begin consumption at age 17 or later, with the maintenance of abstinence the speed of recovery 
in global cognitive ability is higher than in those who began consumption at age 16 or earlier.
Two hypotheses might explain the lower IQ of the OSU ≤ 16 group: the existence of a worse cogni-
tion prior to consumption or a higher effect of overall neurotoxicity associated to the age of OSU. In the 
case of lower VIQ, some results seem to be more indicative of the hypothesis of lower cognitive ability 
prior to consumption: (a) participants in this group had a higher rate of family history of SUD, a char-
acteristic related to the presence of cognitive impairment in their descendants even if the latter have not 
consumed29; (b) the estimate is made from the Vocabulary subtest, where performance is more preserved 
after neurological damage, thus making it the most widely accepted as a measure of premorbid cognitive 
functioning35. In contrast, the origin of the low PIQ raises more questions. In this case, other evidence 
supports the hypothesis of a greater brain damage arising from SUD: (a) although the Block Design 
subtest is commonly used as a measure of premorbid PIQ, its performance is sensitive to attacks to the 
central nervous system37; (b) since this task is related to perceptual organization35, whose neurological 
substrate shows a critical maturation period prior to age 1638, consumption at age 16 or earlier could 
Neuropsychological tasks OSU ≤ 16 (N = 41) OSU ≥ 17 (N = 39)
Age and Years of 
education covariables
Age, Years of education, 
Duration of drug use (yr), 
Vocabulary and Block 
Design Scores covariables
F p values
Effect 
Size F p values
Effect 
Size
PREMORBID IQ
  Vocabulary (WAIS-III). Direct 
Score 40.24 ± 6.76 44.97 ± 5.94 7.71 0.007 0.09
  Block Design (WAIS-III). 
Direct Score 41.09 ± 11.56 46.31 ± 10.06 5.74 0.019 0.07
ATTENTION SPAN
  Digits Forward (WAIS-III). 
Direct Score 8.10 ± 1.63 8.77 ± 1.88 1.52 0.221 0.02 0.40 0.530 0.10
PROCESSING SPEED
 TMT-A (Seconds) 27.15 ± 8.84 22.28 ± 7.04 9.42 0.003 0.11 0.99 0.322 0.17
VISUOSPATIAL PERCEPTION
  Judgment of Line Orientation 
Test
 Number of correct answers 23.60 ± 3.90 25.44 ± 3.19 5.30 0.024 0.07 0.12 0.726 0.64
 Reaction Time (milliseconds) 7487.18 ± 2576.25 6455.85 ± 2044.21 4.47 0.038 0.06 0.05 0.822 0.05
VERBAL MEMORY
  AVLT (Number of recorded 
words) 0.40
a 0.531 0.01 0.34a 0.847 0.13
 A1 5.24 ± 1.32 5.82 ± 1.60 1.67 0.201 0.02 0.87 0.355 0.15
 A2 8.12 ± 1.82 8.15 ± 1.84 0.00 0.977 0.00 0.49 0.488 0.11
 A3 9.93 ± 2.01 10.13 ± 2.52 0.11 0.739 0.00 0.31 0.577 0.09
 A4 11.02 ± 1.98 11.23 ± 2.21 0.08 0.775 0.00 0.08 0.775 0.06
 A5 11.80 ± 2.21 12.21 ± 1.92 0.82 0.367 0.00 0.16 0.687 0.07
 Total words from list A 46.10 ± 8.09 47.54 ± 8.47 0.41 0.523 0.01 0.00 0.994 0.05
 B1 (interference list) 4.98 ± 1.33 5.00 ± 1.70 0.00 0.955 0.00 0.13 0.720 0.07
 A6 9.27 ± 2.96 9.74 ± 2.82 0.58 0.448 0.01 0.71 0.403 0.13
 A7 9.07 ± 2.90 9.38 ± 2.73 0.41 0.522 0.01 0.10 0.753 0.06
 REC A/15 13.49 ± 1.69 13.35 ± 1.66 0.20 0.656 0.00 0.39 0.536 0.09
Table 3.  Results of ANCOVA, MANCOVA or RM MANCOVA analyses considering two or five 
covariables, with mean and standard deviations of the groups of patients in a first group of 
neuropsychological tasks. aResults of the RM MANCOVA for five trials. yr: years; OSU ≤ 16: Onset of 
substance use at age 16 or earlier; OSU ≥ 17: Onset of substance use at age 17 or later; IQ: intelligence 
quotient;WAIS-III: Wechsler Adult Intelligence Scale-Revised Third Edition; TMT-A: Trail Making Test part 
A; AVLT: Auditory Verbal Learning Test; A1, A2, A3, A4, A5: Number of words recalled in 5 consecutive 
trials from list A; B1: Number of words recalled from list B; A6: Number of words recalled from list A 
immediately after the recall list B; A7: Delayed recall of List A after 15 minutes; REC A/15: Number of 
correctly recognized words from list A.
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Executive functions tests OSU ≤ 16 (N = 41) OSU ≥ 17 (N = 39)
Age and Years of 
education covariables
Age, Years of education, 
Duration of drug use 
(yr), Vocabulary and 
Block Design Scores 
covariables
F p values
Effect 
Size F p values
Effect 
Size
Digits Backwards (WAIS-III). 
Direct Score 5.88 ± 2.00 6.33 ± 1.97 0.62 0.433 0.01 0.01 0.975 0.05
TMT-B (seconds) 73.20 ± 33.0 67.51 ± 36.48 0.96 0.331 0.01 0.24 0.623 0.08
Tower of Hanoi
 Number of movements 29.95 ± 11.71 24.95 ± 9.26 3.90 0.045 0.05 1.56 0.217 0.23
 Number of errors 1.68 ± 2.00 1.34 ± 2.17 1.27 0.262 0.02 0.21 0.651 0.07
 Reaction Time (seconds) 209.38 ± 145.90 149.97 ± 78.95 7.22 0.009 0.09 0.14 0.712 0.07
WCST
 Trials administered 91.23 ± 18.22 91.10 ± 18.41 0.10 0.752 0.00 1.71 0.195 0.25
 Total correct 73.95 ± 11.79 72.44 ± 8.60 0.03 0.870 0.00 0.68 0.412 0.13
 Total errors (%) 17.35 ± 8.58 18.74 ± 7.33 0.63 0.429 0.01 1.51 0.223 0.29
 Perseverative errors (%) 4.80 ± 7.09 5.08 ± 4.86 0.00 0.952 0.00 1.00 0.321 0.18
 Non-perseverative errors (%) 11.35 ± 3.27 15.23 ± 12.24 3.49 0.066 0.04 0.18 0.666 0.07
 Conceptual level responses (%) 76.23 ± 15.72 76.41 ± 10.74 0.06 0.806 0.00 0.62 0.434 0.12
 Categories completed 5.85 ± 0.80 5.72 ± 1.08 0.35 0.554 0.01 0.41 0.522 0.10
 Trials to first category 14.65 ± 13.20 15.72 ± 18.83 0.04 0.853 0.00 1.30 0.258 0.20
 Failure to maintain set 0.90 ± 1.26 0.95 ± 1.52 0.18 0.693 0.00 0.76 0.387 0.14
 Learn to learn − 1.68 ± 4.29 − 1.15 ± 4.45 0.37 0.548 0.01 0.02 0.889 0.05
 Reaction Time (milliseconds) 3307.65 ± 1256.26 2950.62 ± 1324.49 1.31 0.256 0.02 0.04 0.836 0.06
Iowa Gambling Task
 Total of the 100 trials 1.84 ± 20.82 12.92 ± 31.52 2.15 0.147 0.03 1.92 0.171 0.28
Table 4.  Results of ANCOVA or MANCOVA analyses considering two or five covariables, with mean 
and standard deviations of the groups of patients on executive function tests. OSU ≤ 16: Onset of 
substance use at age 16 or earlier; OSU ≥ 17: Onset of substance use at age 17 or later; WAIS-III: Wechsler 
Adult Intelligence Scale-Revised Third Edition; yr: years. TMT-B: Trail Making Test part B; WCST: 
Wisconsin Card Sorting Test.
Neuropsychological tasks Adjusted R F IVa β Standardized p values Tolerance VIF
TMT-A (seconds) 0.29 16.84 Duration of drug use (yr) − 0.42 0.0001 0.91 1.09
Block Design 
(Direct Score) 0.26 0.02 0.91 1.09
Judgment of Line Orientation Test
 Number of correct answers 0.34 41.72 Block Design (Direct Score) 0.59 0.0001 1.00 1.00
 Reaction Time (milliseconds) 0.17 9.22
Age of onset of 
substance use 
(yr)
− 0.26 0.01 0.99 1.01
Block Design 
(Direct Score) − 0.33 0.002 0.99 1.01
Tower of Hanoi
 Number of movementsb
 Reaction Time (seconds) 0.20 19.12 Duration of drug use (yr) 0.46 0.0001 1.0 1.0
Table 5.  Multiple linear regression for each neuropsychological task that has shown differences between 
groups considering the independent variables Age of onset of substance use, Age, Years of education, 
Duration of drug use, Vocabulary and Block Design Scores; for the total sample. aOnly significant 
variables are presented that comprise each explicative model. bAny explicative model was significant. IV: 
Independent Variables; VIF: Variance inflation factor; TMT-A: Trail Making Test part A; yr: years.
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promote aberrant synaptic reorganizations that would chronically alter its functionality. However, it is 
noteworthy that, contrary to this second hypothesis, visuospatial deficits have been found in patients 
with a family history of SUD11 as well as lower PIQ associated with development of SUD in adulthood39, 
which would support the hypothesis of a worse premorbid PIQ. Unfortunately, the design of our study 
does not allow us to clarify these issues at the moment.
In addition, the OSU ≤ 16 group showed lower speed of processing and slower visuoperceptual skills, 
as well as higher deficits in planning. However, no differences were observed in tasks of attention, ver-
bal memory, working memory, cognitive flexibility or abstract reasoning, nor were there alterations in 
the processes of risk decision-making. Moreover, when premorbid IQ and duration of drug use were 
controlled in the analyses, all cognitive differences between groups disappeared. The linear regression 
analyses with the total sample allowed us to elucidate these results.
At lower PIQ scores, the patients performed worse in the task of visual perception and showed slower 
processing speed. Therefore, we cannot confirm that consumption at age 16 or earlier is related to higher 
deficits in these skills since the lower premorbid IQ interferes with their performance.
However, it should be highlighted that the age of OSU also modulated the visuoperceptual perfor-
mance of the participants: when it was lower, they needed more time to respond to the stimuli in this 
task. This would support the idea that drug consumption at age 16 or earlier may alter the optimal 
neurodevelopment, and its consequence would imply specific visuoperceptual deficits. Since in our area 
of study no previous work had considered this cognitive function24–26,32, more data are needed to sustain 
this hypothesis.
Nevertheless, our results indicate that the variable with greater explanatory power regarding planning 
abilities and processing speed is the duration of drug use. This is consistent with evidence that repeated 
use of substances is associated with morphological brain changes in both gray and white matter. In 
polydrug patients, as consumption becomes chronic, it has been observed greater volume reduction in 
the prefrontal cortex40, associated with planning skills41. In cocaine users, increased abnormalities in the 
corpus callosum also correlate with greater impulsivity and lack of planning42,43. Therefore, differences 
in duration of drug use could underlie some results that, unlike ours, have observed different executive 
functioning and processing speed between the OSU ≤ 16 and OSU ≥ 17 groups25.
The interpretation of our results is subject to limitations. Most of the sample consisted of polydrug 
users, making it impossible to separate the differential effect of each type of substance on neurocogni-
tion16. Although this is a frequent limitation with this type of patients44, in our study its effect is relatively 
controlled since the groups did not differ in the main substances used. Future studies should considered 
the main substance associated with the diagnosis of dependence, since it is possible that it plays a role 
in the explanatory model of performance in visual perception, planning and processing speed, together 
with the age of OSU, duration of drug use and PIQ. In addition, it would be interesting to incorporate 
designs that contribute to clarify the etiology and clinical course of cognitive deficits observed in the 
OSU ≤ 16 group and its relation to clinical severity.
Although our results should be interpreted with caution, they may have clinical implications. SUD 
patients may benefit from cognitive rehabilitation6,7, because cognitive deficits and clinical course are 
related12. Therefore, neuropsychological assessment and rehabilitation in SUD treatment programs, espe-
cially in patients with OSU ≤ 16, could improve adherence and response to interventions. This is relevant 
because our results confirm that the duration of drug use is related to cognitive impairment on execu-
tive performance and processing speed, which could increase the difficulty of rehabilitation15. Finally, it 
would be interesting to develop longitudinal studies assessing the presence of cognitive disorders in the 
OSU ≤ 16 group prior to consumption and, therefore, help to consider this age group as a target popu-
lation in primary prevention programs.
In conclusion, the cut-off age considered in our study allows us to differentiate typologies of polydrug 
addicts in relation to their clinical severity and cognitive functioning, so that taking them into consid-
eration could contribute to improve SUD prevention and treatment programs. The OSU ≤ 16 group pre-
sents a more severe clinical pattern: higher rates of family history of SUD, greater number of relapses, a 
consumption pattern characterized by the use of more substances and the need for interment to achieve 
similar abstinence. They also show lower IQ scores, higher visuoperceptual and planning deficits and 
slower processing speed. The lower VIQ could be a premorbid characteristic, and the lower PIQ and 
visuoperceptual skills could be either the result of consumption on the neurodevelopment as character-
istics prior to the SUD. Further work is required to shed light on this issue. The difficulties in planning 
and greater slowdown in information processing may be related to the duration of drug use, which make 
it highly relevant both for the study of neuropsychological characteristics in the field of addictions as well 
as for tertiary prevention programs.
Methods
Participants. In a cross-sectional study design, we enrolled 80 patients linked to different healthcare 
resources for SUD treatment. All were male, given the high prevalence of this gender in admissions to 
treatment for SUD45 and to avoiding bias on the results due to sex differences46. Informed consent was 
obtained from all participants, who were not compensated for their collaboration in the study.
The inclusion criteria were: current or past diagnosis of SUD, ongoing treatment, confirmed by a diag-
nostic interview according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text 
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Revised (DSM-IV-TR)47 criteria, established by their treating clinician or a trained clinical researcher; 
with abstinence for at least 4 months at the time of the study (excluding caffeine or nicotine consump-
tion), confirmed by urinalysis. The exclusion criteria were: female gender; age below 18 and above 55; 
presence of mental retardation or pervasive developmental disorder, history of traumatic brain injury or 
neurological injury, or cognitive or physical impairment that would preclude the correct application of 
the selected tests; and presence of a comorbid axis I mental disorder confirmed by a diagnostic interview 
according to DSM-IV-TR criteria.
The patients were added consecutively according to the centers’ referral, without taking into account 
the OSU variable. After collecting the information, the sample was classified into two groups depend-
ing on whether substance use had begun at age 16 or earlier (OSU ≤ 16; n = 41) or at age 17 or later 
(OSU ≥ 17; n = 39). The age cut-off was based on neurodevelopmental characteristics, similarly to what 
had been done in previous studies with cannabis consumers28–31.
Experimental protocol of this study was approved by the University of Barcelona’ ethic committee and 
the methods were carried out in accordance with the ethical principles of the declaration of Helsinki.
Clinical measures. Information was collected on sociodemographic (age, marital status, educational 
and economic status) and clinical (presence of organic pathology, psychiatric and substance use family 
history, suicidal attempts, past treatment for SUD, consumption pattern, type of drugs used, age of onset 
substance use, duration of drug use, typology of treatment regimen, medication, abstinence periods 
and relapses) variables, using a structured interview. This information was confirmed with the medical 
history of the centers database and with the patients treating psychiatrist. Furthermore, daily consump-
tion of cigarettes and caffeine beverages was recorded. The Fagerström test of nicotine dependence48 was 
administered to smokers. All participants were administered the Clinical Global Impression question-
naire (CGI)49, as a subjective measure of the clinical severity.
Neuropsychological assessment. Cognitive functioning was assessed by a comprehensive battery 
of cognitive measures, extensively validated and routinely used35. The administration of the tests was 
distributed into two separate sessions of two hours each, always in a fixed order alternating verbal and 
manipulative tests. All participants completed the battery. The Vocabulary and Block Design subtests of 
the Wechsler Adult Intelligence Third Edition Scale Revised (WAIS-III)50 were administered to assess 
the premorbid VIQ and PIQ, respectively35. Attention span was measured with the Digit Span Subtest of 
the WAIS-III. The TMT-A51 was administered as a measure of processing speed. We assessed visuospa-
tial perception with the JLOT52, in there computerized version of Estévez-González (2001). Declarative, 
immediate and delayed memory variables were assessed with the RAVLT53. Finally, we measured the per-
formance in different components of executive functions: the TMT-B51 and the Digits Backwards Subtest 
of the WAIS-III for the working memory; the Tower of Hanoi54, in there four disk computerized version 
of González-Vilches (2000) for the planning and problem solving; the WCST55, in there computerized 
version of Estévez-González (2001), for the cognitive flexibility, reasoning and problem solving; and the 
IGT56, in there computerized version of Kilgard (1997), for the decision making with risk.
Statistical analysis. Differences between groups in the sociodemographic and clinical variables were 
explored with the Mann-Whitney U test (U) or with the Chi Square test for categorical variables. If the 
quantitative data fulfilled the necessary conditions, the Student’s t-test (t) was used; when the conditions 
were not met, the nonparametric Mann-Whitney U test (U) was used instead.
Differences in neuropsychological performance were assessed using analysis of covariance (ANCOVA), 
multiple analysis of covariance (MANCOVA) or with repeated measures MANCOVA (RM MANCOVA), 
depending on the task. The Bonferroni test was applied in all analyses to reduce the occurrence of a type 
1 error. The effect size was calculated with the partial Eta squared (ηp2) index, assuming a value of 0.01 
as low, of 0.04 as moderate and of 0.1 as high57. Age and years of education were considered as covari-
ates, given their known effects on cognitive performance58,59 and because they presented high standard 
deviations in both groups.
The two groups differed in duration of drug use and in the scores obtained in the Vocabulary and 
Block Design subtests of the Wechsler Adult Intelligence Scale-Revised Third Edition (WAIS-III). These 
subtests are considered measures of premorbid IQ35,60. Moreover, the effects of duration of drug use 
on neuropsychological performance are well known35,44. Thus, we explored their possible influence on 
the neuropsychological results, together with age and years of schooling. This was done in two steps. 
Firstly, the analyses of covariance were repeated for all the cognitive tasks considering the five covari-
ates. Secondly, a confirmatory analysis was performed using a stepwise regression analysis, in order to 
study their influence on those neuropsychological tasks in which a loss of significance was observed 
when compared to the first analysis. We consider the total sample, considering the neuropsychological 
measures as dependent variables and introducing as independent variables the age of OSU, age, years of 
schooling and duration of consumption, and the scores in the Vocabulary and Block Design subtests. 
Data were analyzed using the Statistical Package for the Social Sciences (SPSS; version 15.0), considering 
bilateral statistical significance with an established type 1 error at 5% (p < 0.05).
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